Timothy S. Cabral, a director at Doximity, Inc. (NYSE:DOCS), recently sold 20,000 shares of the company's Class A Common Stock, according to a filing with the Securities and Exchange Commission. The shares were sold at a weighted-average price of approximately $42.07, totaling $841,306. This transaction was executed automatically under a pre-established Rule 10b5-1 trading plan, which Cabral adopted earlier this year.
Following the sale, Cabral holds 11,074 shares of Class A Common Stock directly. Additionally, the filing detailed that Cabral exercised stock options for Class B Common Stock, which converted into Class A Common Stock at no cost. These transactions reflect Cabral's ongoing management of his equity position in the company.
In other recent news, Doximity has been the subject of significant attention from various analyst firms. Barclays (LON:BARC) has upgraded Doximity's shares to Overweight, citing end market stabilization and growth inflection. The firm also increased the price target for Doximity to $52.00, showing increased confidence in the company's growth potential and market strategy. BofA Securities and Jefferies also raised their price targets for Doximity to $45 and $43 respectively, reflecting an uptick in advertising spend and the success of new product introductions.
In addition to these upgrades, Doximity has seen some major internal developments. The company recently re-elected two directors and ratified Deloitte & Touche LLP as its independent registered public accounting firm for the fiscal year ending March 31, 2025.
Other analyst firms such as Canaccord Genuity, Truist Securities, and Needham have also shown positive outlooks on Doximity's prospects. Canaccord Genuity expressed confidence in Doximity's new Portal offering, Truist Securities increased its FY25 revenue estimate for Doximity to $522.8 million, and Needham upgraded its rating on Doximity to Buy, citing strong momentum with large customers and new product innovations.
These recent developments highlight a generally positive outlook on Doximity's growth trajectory and financial performance.
InvestingPro Insights
Doximity's recent insider transaction occurs against a backdrop of strong financial performance and market valuation. According to InvestingPro data, the company boasts a market capitalization of $7.76 billion and trades at a P/E ratio of 49.25, indicating investors' high expectations for future growth.
InvestingPro Tips highlight Doximity's impressive gross profit margins, which are reflected in the data showing a gross profit margin of 89.65% for the last twelve months as of Q1 2023. This exceptional profitability metric underscores the company's efficient operations and strong market position in the healthcare technology sector.
Additionally, Doximity's stock has shown remarkable strength, with InvestingPro data revealing a 93.2% price total return over the past year. This performance aligns with another InvestingPro Tip noting that the stock is trading near its 52-week high, currently at 93.29% of that peak.
These insights provide context to Timothy S. Cabral's recent stock sale, suggesting it may be part of a planned diversification strategy rather than a reflection on the company's prospects. Investors seeking a more comprehensive analysis can access 13 additional InvestingPro Tips for Doximity, offering a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.